Grüns has launched ‘superfood’ gummies designed to address nutritional deficiencies. The product boasts over 60 ingredients, featuring organic fruits and vegetables, prebiotic fiber, and components typical of greens supplement powders.
Established in 2023 by Chad Janis, Grüns has quickly emerged as one of the prominent brands within the U.S. greens supplement market. This acquisition is part of Unilever’s ongoing strategic shift, which includes the recent spin-off of its ice cream division and the integration of its food segment with McCormick.
This strategy aims to enhance Unilever’s position as a leading brand in the home and personal care sector, emphasizing premium offerings and digital sales while seeking to strengthen its presence in the U.S. and Indian markets.
Grüns is sold through both retail and direct-to-consumer channels nationwide. Currently, the brand serves over one million customers and has accumulated more than 95,000 five-star reviews, with roughly 10 million gummies shipped daily.
In 2024, the company broadened its range to include Grüns Kids for younger audiences and Nütrops for cognitive benefits, followed in 2025 by Immün for immune health support and Jüced for energy enhancement.
Regarding the acquisition, Unilever Wellbeing CEO Jostein Solheim expressed: “We are thrilled to welcome Grüns into the Unilever family. As a leader and true innovator in the greens supplement category, what sets Grüns apart is its focused portfolio of science-backed products that people genuinely enjoy, trust, and consistently use. This combination of efficacy and experience is powerful, and together we see a significant opportunity to scale the brand within our Wellbeing business.”
Chad Janis, Grüns’ CEO, remarked: “Our customers are the reason Grüns exists, and this partnership is ultimately for them. With Unilever behind us, we can reach more people, move faster, and continue raising the bar on what an enjoyable daily wellness habit can be.”
The deal is anticipated to finalize later this year, pending standard regulatory approvals and closing conditions, although the financial details remain undisclosed.